RBM7 and cancer: Countering the axis of RBM7 and P-TEFb might prove especially effectual in combination with bulky DNA-adduct-inducing platinum-based drugs such as cisplatin, which shows improved therapeutic outcome in NER-deficient cancers (Dietlein et al., 2014, Gavande et al., 2016).